Natrix Sciences Ltd. is an EU-cGMP licensed pharmaceutical facility producing generic medicines. With fifteen years of experience, the company is a Contract Development Manufacturing Organization ("CDMO") that specializes in the formulation of modified release solid oral dosage forms i.e. powder, granules and pellets to be filled into hard gelatine capsules. The company's main exporting countries are located within Europe with a recent focus to enter into new territories in new markets.In addition to the above, Natrix Sciences Ltd. through further investments has positioned itself as a strategic partner for innovative research and development projects stemming from emerging industries. Its latest investment comes in the form of a joint venture with Zenabis Global Inc. (recently acquired by Hexo Corp in June 2021.). The latter is presented through the incorporation of ZenPharm Ltd. that was awarded its EU-cGMP license in January 2021 and its Medicinal Cannabis License in May 2021, satisfying all requirements to operate and trade in medicinal cannabis. The synergistic expertise between Zenabis Global Inc. and Natrix Sciences Ltd. enables ZenPharm Ltd. to established itself as a European Head Quarter for Zenabis Global Inc. for the processing and distribution of medicinal cannabis in European countries.